Market News & Trends
Bluejay Announces Receipt of PRIME Designation From EMA for Chronic Hepatitis Delta Virus Infection Treatment
Bluejay Therapeutics, Inc. recently announced the European Medicines Agency (EMA) has granted Priority Medicine (PRIME) designation to BJT-778 for the treatment of Chronic Hepatitis Delta…
IGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer’s Agitation
IGC Pharma, Inc. recently announced the results of an interim analysis of its ongoing Phase 2 trial investigating IGC-AD1 as a treatment for Agitation in…
Pace Life Sciences Adds Liquid Capsule Filling Technology, Acquires New Jersey Laboratory From Curia & Appoints Dawn Von Rohr as Division President
Pace Life Sciences makes three major announcements for expansion of services, key acquisition, and new division Vice President….
Nykode Therapeutics Announces Topline Conclusions Affirming Prolonged Clinical Benefits From Matured Survival Data in Phase 2 C-02 Trial in Advanced Cervical Cancer
Nykode Therapeutics ASA recently announced key conclusions from the updated analysis from the Phase 2 VB-C-02 trial. The trial investigates the use of Nykode’s wholly…
CAMP4 Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Study for Potential First-in-Class Therapeutic for Urea Cycle Disorders
Lead program in urea cycle disorders highlights power of CAMP4’s RAP Platform to increase gene expression using programmable, targeted medicines, with clinical candidate moving from screen-to-clinic within 3 years….
Lisata Therapeutics Announces US FDA Rare Pediatric Disease Designation Granted to LSTA1 for the Treatment of Osteosarcoma
Lisata Therapeutics, Inc. recently announced the US FDA has granted Rare Pediatric Disease Designation (RPDD) to LSTA1, the company’s lead product candidate, for the treatment…
SciSparc: MitoCareX Unveils Groundbreaking Discovery of Small Molecule Structure in Anti-Cancer Research
SciSparc Ltd. recently announced MitoCareX Bio Ltd., the company’s venture with Dr. Alon Silberman that focuses on drug discovery and the development of cancer therapeutics…
Bayer & Thermo Fisher Scientific Collaborate to Increase Patient Access to Precision Cancer Medicines
Bayer AG and Thermo Fisher Scientific Inc. recently announced they will develop next-generation sequencing (NGS)-based companion diagnostic assays (CDx) together. These will help identify patients…
Lonza Signs Agreement to Acquire Large-Scale Biologics Site in Vacaville (US) From Roche
Lonza recently announced it has signed an agreement to acquire the Genentech large-scale biologics manufacturing site in Vacaville, CA, from Roche for….
Orchard Therapeutics Outlines US Launch Plans for the Only Approved Therapy for Children With Early Onset Metachromatic Leukodystrophy
Orchard Therapeutics recently announced the details of its US commercial launch of Lenmeldy (atidarsagene autotemcel), formerly known as OTL-200, the first FDA-approved therapy for the….
Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial
Immix Biopharma, Inc. recently announced Memorial Sloan Kettering Cancer Center as lead clinical site for its NXC-201 relapsed/refractory AL Amyloidosis multi-site clinical trial. “We are…
OKYO Pharma to Release New & Comprehensive Data GFrom Phase 2 Dry Eye Disease Trial
OKYO Pharma Limited recently announced it will be releasing new and comprehensive efficacy data readout from the Phase 2 trial of OK-101 in dry eye disease on….
ACELYRIN Announces Positive Phase 1/2 PoC Data for First Subcutaneous Anti-IGF-1R to Demonstrate Clinical Responses in Thyroid Eye Disease
ACELYRIN, INC. recently announced positive proof-of-concept data from an ongoing Phase 1/2 trial of lonigutamab in thyroid eye disease (TED). Lonigutamab is a subcutaneously….
RespireRx Pharmaceuticals Reports Preclinical Research Demonstrating the Ability of its Lead Clinical AMPAkine to Improve Bladder Function After Spinal Cord Injury
RespireRx Pharmaceuticals Inc. recently announce that, as part of an ongoing collaboration, a scientist team led by Dr. David Fuller of the University of Florida…
Silo Pharma Exercises Option for Exclusive License Agreement for First-in-Class PTSD & Stress-Induced Anxiety Therapeutic
Silo Pharma, Inc. recently announced it has exercised its option to license SPC-15, a prophylactic treatment for stress-induced affective disorders including anxiety and PTSD, from…
TFF Pharmaceuticals Announces Update on Clinical Programs
TFF Pharmaceuticals, Inc. recently announced data updates and strategic prioritization of its clinical programs. Based on positive data from the ongoing Phase 2 study of…
Petros Pharmaceuticals Successfully Launches AI Tool in Collaboration With Multi-Billion-Dollar Software Provider
Petros Pharmaceuticals, Inc. recently announced it has successfully launched its artificial intelligence (AI) tool developed as a result of its collaboration with a multi-billion-dollar software developer.…
Revive Therapeutics to Submit Type C Meeting Request With FDA for Bucillamine to Treat Long COVID
Revive Therapeutics Ltd. recently announced the FDA advised the company to submit a Type C meeting request to discuss evaluating a proposed Phase 2 clinical…
Hovione & GEA Strengthen Partnership to Advance Continuous Tableting Technology
Hovione and GEA recently announced the next stage of their partnership, with new development agreements, the launch of the ConsiGma CDC flex as well as…
ReciBioPharm & GeneVentiv Therapeutics Partner to Advance First AAV-Based Gene Therapy for Haemophilia Patients With Inhibitors
ReciBioPharm has recently announced a collaboration agreement with GeneVentiv Therapeutics to advance development of an Adeno-Associated Virus (AAV)-based universal gene therapy for….
